依鲁替尼治疗与高血压的关联研究
该回顾性研究比较了144例B细胞恶性肿瘤患者接受依鲁替尼(n=93)或传统化学免疫治疗(n=51)后血压变化。结果显示依鲁替尼组收缩压和舒张压随时间显著升高,而传统化学免疫治疗组无显著变化;治疗1个月时依鲁替尼组收缩压显著升高(>10 mm Hg)的比例为36.6%,高于传统化学免疫治疗组的7.9%。多数接受依鲁替尼治疗且随访时存在高血压的患者未得到充分的血压管理。
要点
- 依鲁替尼治疗与血压升高相关,传统化学免疫治疗未见显著血压变化。
- 治疗1个月时依鲁替尼组36.6%患者收缩压升高>10 mm Hg,传统化学免疫治疗组为7.9%。
- 61.2%的依鲁替尼治疗患者随访时存在高血压但未接受充分血压管理。
核心结论
- 依鲁替尼与高血压的发生及血压恶化相关,心脏科和肿瘤科医生需警惕此心脏毒性以及时管理血压升高。
研究设计与样本
- 回顾性研究纳入144例B细胞恶性肿瘤患者,依鲁替尼组93例,传统化学免疫治疗组51例,评估治疗开始后1、2、3和6个月血压变化。
主要发现
- 两组基线高血压患病率分别为63.4%和66.7%,年龄、性别及基线心脏合并症无差异。
- 依鲁替尼组收缩压和舒张压随时间较基线显著升高,传统化学免疫治疗组无显著血压变化。
- 基线高血压状态不影响血压随时间的变化程度。
- 治疗1个月时,依鲁替尼组36.6%患者收缩压升高>10 mm Hg,传统化学免疫治疗组为7.9%。
- 依鲁替尼组随访时61.2%高血压患者未接受充分血压管理(未增加或加用降压药物)。
临床怎么用
- 对接受依鲁替尼治疗的患者应定期监测血压,及时调整降压治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ibrutinib is a tyrosine kinase inhibitor most commonly associated with atrial fibrillation. However, additional cardiotoxicities have been identified, including accelerated hypertension. The incidence and risk factors of new or worsening hypertension following ibrutinib treatment are not as well known. METHODS: We conducted a retrospective study of 144 patients diagnosed with B cell malignancies treated with ibrutinib (n=93) versus conventional chemoimmunotherapy (n=51) and evaluated their effects on blood pressure at 1, 2, 3 and 6 months after treatment initiation. Descriptive statistics were used to compare baseline characteristics for each treatment group. Fisher's exact test was used to identify covariates significantly associated with the development of hypertension. Repeated measures analyses were conducted to analyse longitudinal blood pressure changes. RESULTS: Both treatments had similar prevalence of baseline hypertension at 63.4% and 66.7%, respectively. There were no differences between treatments by age, sex and baseline cardiac comorbidities. Both systolic and diastolic blood pressure significantly increased over time with ibrutinib compared with baseline, whereas conventional chemoimmunotherapy was not associated with significant changes in blood pressure. Baseline hypertensive status did not affect the degree of blood pressure change over time. A significant increase in systolic blood pressure (defined as more than 10 mm Hg) was noted for ibrutinib (36.6%) compared with conventional chemoimmunotherapy (7.9%) at 1 month after treatment initiation. Despite being hypertensive at follow-up, 61.2% of patients who were treated with ibrutinib did not receive adequate blood pressure management (increase or addition of blood pressure medications). Within the ibrutinib group, of patients who developed more than 20 mm Hg increase in systolic blood pressure, only 52.9% had hypertension management changes. CONCLUSIONS: Ibrutinib is associated with the development of hypertension and worsening of blood pressure. Cardiologists and oncologists must be aware of this cardiotoxicity to allow timely management of blood pressure elevations.
引用
- Lee DH, Hawk F, Seok K, et al. Association between ibrutinib treatment and hypertension. Heart. 2021. PMID: 34210750. doi:10.1136/heartjnl-2021-319110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。